Phase 2 clinical trial of sunvozertinib shows 61 per cent anti-tumour activity response, higher than any previous candidates, according to paper in The Lancet Respiratory Medicine.
Novartis geht mit BeiGene vielversprechende Kooperation ein nzz.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nzz.ch Daily Mail and Mail on Sunday newspapers.